INmune Bio, Inc.
INMBNASDAQHealthcare● Active
$1.29
+$0.05(+3.63%)
Market Cap$34162057
P/E Ratio—
52W High$11.64
52W Low$1.09
INmune Bio, Inc. (INMB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INMB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.20
Est. -$0.24 · +18.4%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 6-Quarter EPS Beat Streak
INMB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.19 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.24 | -$0.20 | +18.4% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.27 | -$0.18 | +33.3% | — | $-0.00B | — |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$0.31 | -$0.24 | +22.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.37 | -$0.34 | +8.1% | — | — | — |
| — Q2 FY2025 | May 8, 2025 | -$0.43 | -$0.43 | +0.0% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.54 | -$0.40 | +25.9% | — | — | — |
| ▼ Q4 FY2024 | Oct 31, 2024 | -$0.49 | -$0.60 | -22.4% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.24
EPS Surpr.
+18.4%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.27
EPS Surpr.
+33.3%
Revenue
—
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.31
EPS Surpr.
+22.6%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.37
EPS Surpr.
+8.1%
Revenue
—
Q2 FY2025
May 8, 2025
EPS Actual
-$0.43
EPS Est.
-$0.43
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.54
EPS Surpr.
+25.9%
Revenue
—
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
-$0.60
EPS Est.
-$0.49
EPS Surpr.
-22.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q3 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q2 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q1 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.21 | $-0.18 | $-0.16 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +18.4% | $1.52 | $1.43 | -5.92% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +33.3% | $1.12 | $1.14 | +1.79% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +22.6% | $1.82 | $1.73 | -4.95% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +8.1% | $2.76 | $2.79 | +1.09% |
| ▲ Q2 FY2025 | May 8, 2025 | +0.0% | $7.14 | $7.09 | -0.70% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +25.9% | $7.73 | $7.41 | -4.14% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -22.4% | $5.95 | $5.85 | -1.68% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +20.6% | $8.59 | $7.91 | -7.92% |
Q2 FY2026-5.92%
Report Date
May 7, 2026
EPS Beat/Miss
+18.4%
Price Before
$1.52
Price After
$1.43
Q1 FY2026+1.79%
Report Date
Mar 30, 2026
EPS Beat/Miss
+33.3%
Price Before
$1.12
Price After
$1.14
Q4 FY2025-4.95%
Report Date
Oct 30, 2025
EPS Beat/Miss
+22.6%
Price Before
$1.82
Price After
$1.73
Q3 FY2025+1.09%
Report Date
Aug 7, 2025
EPS Beat/Miss
+8.1%
Price Before
$2.76
Price After
$2.79
Q2 FY2025-0.70%
Report Date
May 8, 2025
EPS Beat/Miss
+0.0%
Price Before
$7.14
Price After
$7.09
Q1 FY2025-4.14%
Report Date
Mar 27, 2025
EPS Beat/Miss
+25.9%
Price Before
$7.73
Price After
$7.41
Q4 FY2024-1.68%
Report Date
Oct 31, 2024
EPS Beat/Miss
-22.4%
Price Before
$5.95
Price After
$5.85
Q3 FY2024-7.92%
Report Date
Aug 1, 2024
EPS Beat/Miss
+20.6%
Price Before
$8.59
Price After
$7.91
Avg Beat Reaction-2.96%
Avg Miss Reaction-1.68%
Beat Rate7 / 8 quarters
Largest Move-7.92% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INMB ends December
INmune Bio, Inc. (INMB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.20 — beating the analyst consensus of $-0.24 by +18.4%. INMB has beaten EPS estimates for 6 consecutive quarters. The next INMB earnings date is expected around September 1, 2026.
Each quarter, investors track INMB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INMB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INMB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INMB earnings · 5 questionsINmune Bio, Inc.'s next earnings report is expected around September 1, 2026. INMB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INMB historically reports after market close (AMC).
INMB earnings datewhen is INMB earningsINMB next earnings datewhen does INMB report earningsINMB earnings calendar
▸ Source: FMP · INmune Bio, Inc. SEC filings · US GAAP · INmune Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026